tradingkey.logo

Dyne Therapeutics Q2 net loss widens

ReutersJul 28, 2025 8:28 PM


Overview

  • Dyne Therapeutics Q2 net loss widens

  • Co extends cash runway into Q3 2027, supporting multiple clinical milestones

  • Dyne strengthens financial position with public offering and loan facility


Outlook

  • Dyne expects cash runway to extend into Q3 2027

  • Company plans U.S. Accelerated Approval submissions in 2026

  • Dyne anticipates DYNE-251 commercial launch in early 2027

  • Company pursuing approval pathways outside U.S. for DYNE-101 and DYNE-251


Result Drivers

  • R&D INVESTMENT - Increased R&D expenses were $99.2 million


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

Miss

-$0.97

-$0.95 (15 Analysts)

Q2 Net Income

Beat

-$110.86 mln

-$112.60 mln (13 Analysts)

Q2 Operating Income

Beat

-$115.79 mln

-$136.50 mln (13 Analysts)

Q2 Basic EPS

-$0.97

Q2 Operating Expenses

$115.79 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Dyne Therapeutics Inc is $44.50, about 77.6% above its July 25 closing price of $9.95

Press Release: ID:nGNXwYFSr

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI